Letermovir
Letermovir is a pharmaceutical drug with 36 clinical trials. Currently 20 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 11 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
10
Mid Stage
15
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
11 of 11 finished
0.0%
0 ended early
20
trials recruiting
36
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Letermovir for CMV Prevention After Lung Transplantation
Clinical Trials (36)
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Letermovir for CMV Prevention After Lung Transplantation
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Letermovir in ART-treated HIV-infected Persons
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 36